Skip to main content
SpringerLink
Log in

Métastases vertébrales des cancers prostatiques

  • Chapter
Métastases vertébrales

  • 371 Accesses

Abstrait

L’os est la localisation préférentielle des métastases des cancers prostatiques. Il est admis que 30 % des patients présentent des métastases osseuses au moment du diagnostic même si ce pourcentage a tendance à diminuer grâce à un diagnostic plus précoce (11) et que de 30 à 50 % d des patients développent ultérieurement des localisations secondaires osseuses (6, 23). Elles représentent un quart de toutes les métastases osseuses traitées dans un service de radiothérapie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Allain YH, Ravenet F, Soret JY et al. (1984) Bilan d’extension des adénocarcinomes prostatiques. Ouest Médical 37: 111–7

    Google Scholar 

  2. Ancri D (1991) Comment interpréter une scintigraphie osseuse ? In: Khouri, Chatelain, Murphy, Denis (eds) Le cancer de la prostate en question. ICI Pharma, Cergy (France) p 148

    Google Scholar 

  3. Bates T, Yarnold JR, Blitzer P, Nelson OS, Rubin P, Maher J (1992) Bone metastasis consensus statement. Int J Radiat Oncol Biol Phys 23: 215–6

    PubMed  CAS  Google Scholar 

  4. Batson OV (1995) The function of the vertebral veins and their role in the spread of metastases. Clin Orthop 312: 4–9

    PubMed  Google Scholar 

  5. Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE (1997) Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma. Eur Urol 32: 391–5

    PubMed  CAS  Google Scholar 

  6. Bolla M, Van Poppel H (1996) Prostate cancer. An insight into screening and local treatment. Eur J Cancer 32A: 1434–5

    Article  PubMed  CAS  Google Scholar 

  7. Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS (1993) Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pre-treatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer 72: 1685–91

    Article  PubMed  CAS  Google Scholar 

  8. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE (1991) Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145: 313–8

    PubMed  CAS  Google Scholar 

  9. Denis L (1988) Analogues de la LH-RH. In: Khoury S, Chatelain D (eds) Urologie: cancer de la prostate. FIIS, Paris, p 351

    Google Scholar 

  10. Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22: 232–40

    Article  PubMed  CAS  Google Scholar 

  11. James ND, Glaholm J (1995) Prostate cancer: what should be studied? Eur J Cancer 31A: 1565–6

    Article  PubMed  CAS  Google Scholar 

  12. Labrie F, Belanger A, Veilleux R et al. (1988) Rationale for maximal androgen withdrawal in the therapy of prostatic cancer. In: Furr BJA, Denis L (eds) Clinical oncology: prostate cancer. Baillère Tindall, London, p 597

    Google Scholar 

  13. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA (1991) A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27: 954–8

    Article  PubMed  CAS  Google Scholar 

  14. MacLennan I, Selim HM, Rubin P (1989) Sequential hemibody radiotherapy in poor prognosis localized adenocarcinoma of the prostate gland: a preliminary study of the RTOG. Int J Radiat Oncol Biol Phys 16: 215–8

    PubMed  CAS  Google Scholar 

  15. Nakano S, Hasegawa Y (1993) Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 71: 1297–302

    Article  PubMed  Google Scholar 

  16. Newling DW, McLeod D, Soloway M, Di Silverio F, Smith P (1992) Distant disease. Cancer 70(1 Suppl): 365–7

    Article  PubMed  CAS  Google Scholar 

  17. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–20

    Article  PubMed  CAS  Google Scholar 

  18. Pollen JJ, Gerber K, Ashburn WL, Schmidt JD (1981) Nuclear bone imaging in metastatic cancer of the prostate. Cancer 47: 2585–94

    Article  PubMed  CAS  Google Scholar 

  19. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, Sathyanarayana JR, Yakemchuk VN, Thomas GM, Erlich LE et al. (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25: 805–13

    PubMed  CAS  Google Scholar 

  20. Prostate Cancer Trialist’s Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355: 1491–8

    Article  Google Scholar 

  21. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (Zoledronic Acid Prostate Cancer Study Group) (2002) A randomized placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate cancinoma. J Natl Cancer Inst 94: 1458–68

    PubMed  CAS  Google Scholar 

  22. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (Zoledronic Acid Prostate Cancer Study Group) (2004) Long term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 96: 879–82

    Article  PubMed  CAS  Google Scholar 

  23. Scardino PT, Weaver R, Hudson MA (1992) Early detection of prostate cancer. Hum Pathol 23: 211–22

    Article  PubMed  CAS  Google Scholar 

  24. Soulié M, Barré C, Beuzeboc P, Chautard D, Cornud F, Eschwege P, Fontaine E, Molinié V, Moreau JL, Péneau M, Ravery V, Rébillard X, Richaud P, Ruffion A, Salomon L, Staerman F, Villers A (2004) Recommandations 2004 en Onco-Urologie: Cancer de la prostate. Prog Urol 14(suppl 1): 913–55

    PubMed  Google Scholar 

  25. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756–64

    PubMed  CAS  Google Scholar 

  26. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (TAX 327 Investigators) (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351: 1502–12

    Article  Google Scholar 

  27. Yamashita K, Denno K, Ueda T, Komatsubara Y, Kotake T, Usami M, Maeda Nakano S, Hasegawa Y (1993) Prognostic significance of bone metastases in patients with metastatic prostate cancer. Cancer 71: 1297–302

    Google Scholar 

  28. Zelefsky MJ, Scher HI, Forman JD, Linares LA, Curley T, Fuks Z (1989) Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens. Int J Radiat Oncol Biol Phys 17: 1281–5

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Bergonié, 229, cours de l’Argonne, 33076, Bordeaux Cedex

    Pierre Richaud (Radiothérapeute)

  2. Institut Paoli-Calmettes, 232, boulevard Sainte-Marguerite, 13273, Marseille

    Agnès Richard-Tallet (Radiothérapeute)

Authors
  1. Pierre Richaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Agnès Richard-Tallet
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Service de Chirurgie Orthopédique et Réparatrice, Hôpital Pellegrin-Tripode, Place Amélie-Raba-Léon, 33076, Bordeaux Cedex

    Vincent Pointillart

  2. Service d’oncologie médicale, Hôpital Saint-André - CHU Bordeaux, 1, rue Jean Burguet, 33075, Bordeaux Cedex

    Alain Ravaud

  3. Institut Bergonié, 229, cours de l’Argonne, 33076, Bordeaux Cedex

    Jean Palussière

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this chapter

Cite this chapter

Richaud, P., Richard-Tallet, A. (2007). Métastases vertébrales des cancers prostatiques. In: Pointillart, V., Ravaud, A., Palussière, J. (eds) Métastases vertébrales. Springer, Paris. https://doi.org/10.1007/978-2-287-33744-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-33744-4_15

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-33743-7

  • Online ISBN: 978-2-287-33744-4

Publish with us

Policies and ethics

Search

Navigation